J. Richalet, J. Herry, and J. Blein, Médecine de l'alpinisme et des sports de montagne, 2006.

J. Richalet, Modifications physiologiques et pathologiques en haute altitude, Présentation. Mars, 2008.

E. Cauchy, Petit manuel de médecine de montagne de l'ampoule à l'oedème pulmonaire et de la randonnée à l'expé himalayenne. Glénat, 2007.

S. Chawla and S. Saxena, Physiology of high-altitude acclimatization, Resonance, vol.253, issue.1???2, pp.538-586
DOI : 10.1007/s12045-014-0057-3

L. Monassier, Médicaments cardiovasculaires : peut-on prédire leur effet en altitude? Cardio & Sport, pp.14-23, 2005.

A. Taylor, High-altitude illnesses: Physiology, risk factors, prevention, and treatment, Rambam Maimonides Medical Journal, vol.2, issue.1, 2011.
DOI : 10.5041/RMMJ.10022

J. Vanderstraeten, Aborder l'altitude en toute sécutiré -prévention du MAM et des oedèmes d'altitude. Revue Médecine Générale, Juin, issue.284, 2011.

J. Richalet and P. Larmignat, -063- 10) Disponible sur internet, Poumon et altitude. Elsevier Masson, issue.6, 2010.
URL : https://hal.archives-ouvertes.fr/hal-00265263

J. Richalet, Le cerveau à très haute altitude, Cerveau&Psycho, issue.40, pp.52-59, 2010.

B. Dicianno, Acute mountain sickness in disability and adaptive sports: Preliminary data, The Journal of Rehabilitation Research and Development, vol.45, issue.4, pp.479-88, 2008.
DOI : 10.1682/JRRD.2007.08.0136

N. Peschanski, Mise au point : aspects neurologiques de la pathologie d'altitude, pp.235-276, 2003.

M. Egli, C. Sartori, and U. Scherrer, Les maladies aiguës liées à la haute altitude. Recommandations pour leur prise en charge et avancées expérimentales récentes : Médecine des voyages, Médecine & Hygiène, vol.61, pp.1007-1020, 2003.

D. Savary, D. Delgado, F. Bussienne, and E. Cauchy, Pathologies d'altitude (dont gelures) Médecine Urgence, p.30, 2010.
DOI : 10.1016/s1959-5182(10)43737-x

J. Richalet, Physiopathologie de l'hypoxie d'altitude, Médecine & Hygiène, issue.54, pp.1062-1068, 1996.

A. Lovis, H. Duplain, L. Nicod, U. Scherrer, and C. Sartori, Maladies liées à l'altitude et consultation de médecine de montagne, Forum Medical Suisse, vol.12, issue.41, pp.789-93, 2012.

J. Coudret, Oedèmes patologiques induits par l'hypoxie d'altitude, Réanimation, issue.10, pp.103-114, 2001.

R. Kedzierewicz and D. Cabane, Mal aigu des montagnes et oedème cérébral de haute montagne, La Revue du Praticien. Janvier, vol.63, issue.1, pp.18-26, 2013.

S. Gallagher and P. Hackett, High-altitude illness, Emergency Medicine Clinics of North America, vol.22, issue.2, pp.329-55, 2004.
DOI : 10.1016/j.emc.2004.02.001

P. Dorosz, D. Durand, L. Jeunne, and C. , Guide pratique des médicaments. Paris: Maloine, 2013.

M. Beaumont, D. Batéjat, C. Piérard, V. Beers, P. et al., Zaleplon and zolpidem objectively alleviate sleep disturbances in mountaineers at a 3,613 meter altitude, Sleep, vol.30, issue.11, p.1527, 2007.

A. Luks, Which Medications Are Safe and Effective for Improving Sleep at High Altitude ? High Altitude, Medicine & Biology. Septembre, vol.9, issue.3, pp.195-203, 2008.

D. Leaf and D. Goldfarb, Mechanisms of action of acetazolamide in the prophylaxis and treatment of acute mountain sickness, Journal of Applied Physiology, vol.102, issue.4, pp.1313-1335, 2006.
DOI : 10.1152/japplphysiol.01572.2005

C. Imray, A. Wright, A. Subudhi, and R. Roach, Acute Mountain Sickness: Pathophysiology, Prevention, and Treatment, Progress in Cardiovascular Diseases, vol.52, issue.6, pp.467-84, 2010.
DOI : 10.1016/j.pcad.2010.02.003

D. Fiore, S. Hall, and P. Shoja, Altitude illness: risk factors, prevention, presentation, and treatment, American Family Physician. Novembre, vol.82, issue.9, pp.1103-1113, 2010.

V. Sevvom, Acute Mountain Sickness, High Altitude Cerebral Edema and High Altitude Pulmonary Edema. School of Physician Assistant Studies, 2008.

A. Luks, S. Mcintosh, C. Grissom, P. Auerbach, G. Rodway et al., Wilderness Medical Society Consensus Guidelines for the Prevention and Treatment of Acute Altitude Illness, Wilderness & Environmental Medicine, vol.21, issue.2, pp.146-55, 2010.
DOI : 10.1016/j.wem.2010.03.002

R. Lagnaoui, F. Depont, A. Fourrier, A. Abouelfath, B. Begaud et al., Patterns and correlates of benzodiazepine use in the French general population, European Journal of Clinical Pharmacology, vol.17, issue.11, pp.523-532, 2004.
DOI : 10.1007/s00228-004-0808-2

C. Site and . Ch, Disponible sur : http://compendium.ch/mpro/ mnr, 15556.

G. Rankin and . Acétazolamide, Marchal university school of medecine, pp.1-5, 2007.

T. Kilner and S. Mukerji, Acute mountain sickness prophylaxis : knowledge, attitudes & behaviours in the Everest region of Nepal. Travel Medicine & Infectious Disease, Novembre, vol.8, issue.6, pp.395-400, 2010.

S. Jackson, J. Varley, C. Sellers, K. Josephs, L. Codrington et al., Incidence and predictors of acute mountain sickness among trekkers on Mount Kilimanjaro, High Altitude Medicine & Biology, vol.11, issue.3, pp.217-239, 2010.
DOI : 10.1089/ham.2010.1003

R. Herraez-hernandez, P. Campins-falco, and A. Sevillano-cabeza, Determination of acetazolamide in human urine samples by reversed-phase high-performance liquid chromatography in the presence of xanthines, Journal of Chromatography B: Biomedical Sciences and Applications, vol.582, issue.1-2, pp.181-188, 1992.
DOI : 10.1016/0378-4347(92)80317-J

P. Campins-falco, R. Herraez-hernandez, and A. Sevillano-cabeza, Application of column-switching techniques to the determination of medium polarity drugs: determination of acetazolamide in urine, Journal of Chromatography B: Biomedical Sciences and Applications, vol.654, issue.1, pp.85-90, 1994.
DOI : 10.1016/0378-4347(94)00005-0

V. Haddad, R. Mas, and A. Legrand, Biochimie clinique conforme au programme du CNCI. Paris : Vernazobres-Grego, 2011.

A. Cadwallader, D. L. Torre, X. Tieri, A. Botrè, and F. , The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: pharmacology, toxicology and analysis, British Journal of Pharmacology, vol.72, issue.1, pp.1-16, 2010.
DOI : 10.1111/j.1476-5381.2010.00789.x

M. Duclos, Evidence on ergogenic action of Glucocorticoids as a doping agent risk. Physician & Sportsmedicine, Octobre, vol.38, issue.3, pp.121-128, 2010.

V. Castelain, T. Lavigne, A. Jaeger, and F. Schneider, Manifestations cardiovasculaires des substances r??cr??atives??: alcool, coca??ne, amph??tamines, ecstasy, h??ro??ne et cannabis, R??animation, vol.14, issue.3, pp.186-95, 2005.
DOI : 10.1016/j.reaurg.2005.02.009

R. Bents, J. Tokish, and L. Goldberg, Ephedrine, Pseudoephedrine, and Amphetamine Prevalence in College Hockey Players, The Physician and Sportsmedicine, vol.24, issue.2, pp.30-34, 2004.
DOI : 10.3109/10550499808995637

C. Saudan, N. Baume, N. Robinson, L. Avois, P. Mangin et al., Testosterone and doping control, British Journal of Sports Medicine, vol.40, issue.Supplement 1, pp.40-61, 2006.
DOI : 10.1136/bjsm.2006.027482

D. Van-de-kerkhof, D. Boer, D. Thijssen, J. Maes, and R. , Evaluation of Testosterone/Epitestosterone Ratio Influential Factors as Determined in Doping Analysis, Journal of Analytical Toxicology, vol.24, issue.2, pp.102-117, 2000.
DOI : 10.1093/jat/24.2.102

D. Handelsman, Indirect androgen doping by oestrogen blockade in sports, British Journal of Pharmacology, vol.52, issue.Suppl 1, pp.598-605, 2008.
DOI : 10.1038/bjp.2008.150

S. Walsh, P. Nuzzo, M. Lofwall, and J. Holtman, The relative abuse liability of oral oxycodone, hydrocodone and hydromorphone assessed in prescription opioid abusers. Drug and Alcohol Dependence, Décembre, vol.98, issue.3, pp.191-202, 2008.

R. Goodwin, W. Darwin, C. Chiang, M. Shih, S. Li et al., Urinary Elimination of 11-Nor-9-Carboxy-??9-tetrahydrocannnabinol in Cannabis Users During Continuously Monitored Abstinence, Journal of Analytical Toxicology, vol.32, issue.8, pp.562-569, 2008.
DOI : 10.1093/jat/32.8.562

M. Huestis, J. Mitchell, and E. Cone, Urinary Excretion Profiles of 11-Nor-9-Carboxy-??9-Tetrahydrocannabinol in Humans after Single Smoked Doses of Marijuana, Journal of Analytical Toxicology, vol.20, issue.6, pp.441-52, 1996.
DOI : 10.1093/jat/20.6.441

A. Vermeeren, Residual Effects of Hypnotics, CNS Drugs, vol.19, issue.1, 2004.
DOI : 10.2165/00023210-200418050-00003

M. Sullivan and E. Evans, Abuse and misuse of antidepressants, Substance Abuse and Rehabilitation, vol.107, 2014.
DOI : 10.2147/SAR.S37917

M. M. Ebbens and J. Verster, Clinical evaluation of zaleplon in the treatment of insomnia, Journal of Nature and Science of Sleep. Février, vol.2010, issue.2, pp.115-141, 2010.

K. Zafren, Prevention of high altitude illness. Travel Medicine and Infectious Disease, Janvier, vol.12, issue.1, pp.29-39, 2014.

. Estimation-fonctionnelle-de-lake-louise, Questionnaire du Score Disponible sur : http://theses.ulb.ac